Chronic Lymphocytic Leukemia Research Consortium

Chronic Lymphocytic Leukemia Research Consortium (CRC) is a multi-institutional program project. It is partially funded by the National Institute of Health, United States. The pipeline products of the company include CRC000 tissue core abstract and CRC 014 for the treatment of B-cell Chronic Lymphocytic Leukemia (CLL). The clinical sites for this company include Moores UCSD Cancer Center, M.D., North Shore-Long Island Jewish Medical System, Anderson Cancer Center, Ohio State University Cancer Center, Dana-Farber Cancer Institute, and Mayo Clinic. Through its tissue core division, it provides the infrastructure for all the pipe line projects. Its laboratory work is conducting at the Burnham Institute and Barts and the London Cancer Center. CRC is headquartered in California, the US.

Street: 
Moores UCSD Cancer Center
City: 
La Jolla
Postcode: 
92093 0820
Federal State : 
United States
WebSite: 
cll.ucsd.edu
Fax: 
1-858-8225660

Company Index Score

Current Index Score Historical Index Score
  • Chronic Lymphocytic Leukemia Research Consortium currently scores 50 % in the index.
  • Chronic Lymphocytic Leukemia Research Consortium is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Chronic Lymphocytic Leukemia Research Consortium is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets